Testing a drug to reduce stress effects on memory in Alzheimer's patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates whether the selective glucocorticoid receptor antagonist, CORT108297, can mitigate stress-related cognitive decline in individuals at risk for Alzheimer's disease. It is a two-week, randomized, placebo-controlled crossover study involving 52 participants, including those with mild cognitive impairment and cognitively normal individuals with risk factors for Alzheimer's. Participants will undergo a brief stressor and provide saliva samples to measure stress hormone responses, followed by cognitive testing after treatment. The study aims to assess the drug's impact on memory and executive function.

Why it matters

Who can join: the full rules

Individuals must meet criteria for mild cognitive impairment due to Alzheimer's disease according to National Institute on Aging (NIA)/Alzheimer's Association recommendations OR be cognitively normal based on clinical and cognitive assessment in the Enrollment Visit and have at least one of the following risk factors for AD:

* Known to have at least 1 apolipoprotein E (APOE) ε4 allele;
* Subjective cognitive concerns with a T score \< 40 on the Multifactorial Memory Questionnaire Satisfaction Scale;
* A first-degree relative with dementia.

Inclusion Criteria for all subjects:

* At least 55 years of age;
* Body mass index \>17 and \<30;
* Post-menopausal (if female)
* Non-smoker;
* Availability of a study partner who has frequent contact with the subject (10+ hours/week in person and by telephone), and is able to provide an independent evaluation of functioning;
* Fluent English speaker;
* Good general health with no disease expected to interfere with the study;
* Willing and able to participate for the duration of the study.

Exclusion Criteria for all subjects:

* Participation in a therapeutic clinical trial at any time during the study;
* Abnormal corrected QT interval using Bazett's formula (QTcB; defined as \> 450 ms for men and \> 470 ms for women) as determined on ECG;
* Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities, including lacunes in critical memory structures including the hippocampus and parahippocampal cortex;
* Bipolar disorder within the past 1 year;
* History of alcohol or drug dependence;
* Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol;
* General surgery within the last 3 months;
* Sensory impairment (poor vision or hearing) significant enough to interfere with ability to provide valid cognitive test data;
* Treatment within the last six months with neuroleptics, sedative hypnotics, or glucocorticoids;
* Treatment within the last six months with medications metabolized by the CYP2C9 or CYP2C19 enzymes, most notably clopidogrel and proton pump inhibitors;
* Concurrent use of a CYP3A inhibitor, including grapefruit juice, and St. John's Wort;
* Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the PI.

Where it's running

• Johns Hopkins School of Medicine
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Cynthia A Munro, PhD — Johns Hopkins School of Medicine
• Study coordinator: Nicholas Bienko, MS
• Email: nbienko1@jhmi.edu
• Phone: 410-550-2036

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aerobic exercise program for older adults with mild cognitive impairment

  This study is testing if a 6-month aerobic exercise program can help older adults with mild cognitive impairment or early Alzheimer's improve their brain health and fitness.

  Recruiting Arizona State University · Phoenix, Arizona · NCT05877196

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease

  A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07717567

• Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers

  This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.

  Recruiting Yale University · New Haven, Connecticut · NCT07602283

• Following memory decline in Alzheimer disease

  This project will use 7T MRI, EEG, blood and stool samples, and memory tests to see if they can track memory decline in people over 55 with Alzheimer's disease or mild cognitive impairment.

  Recruiting Norwegian University of Science and Technology · Trondheim, Trønderlag · NCT07118137

• Fast-track screening to determine eligibility for anti-amyloid treatment using digital cognitive tests and blood biomarkers.

  This project will test whether combining self‑administered digital cognitive tests with blood biomarker results can quickly identify patients referred for memory concerns who may qualify for anti‑amyloid disease‑modifying therapy.

  Recruiting MoCA Clinic and Institute · Greenfield Park, Quebec · NCT07041450

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.